Literature DB >> 17581778

Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET.

Marco Metra1, Christian Torp-Pedersen, John G F Cleland, Andrea Di Lenarda, Michel Komajda, Willem J Remme, Livio Dei Cas, Philip Spark, Karl Swedberg, Philip A Poole-Wilson.   

Abstract

BACKGROUND: It is unclear whether beta-blocker therapy should be reduced or withdrawn in patients who develop acute decompensated heart failure (HF). We studied the relationship between changes in beta-blocker dose and outcome in patients surviving a HF hospitalisation in COMET.
METHODS: Patients hospitalised for HF were subdivided on the basis of the beta-blocker dose administered at the visit following hospitalisation, compared to that administered before.
RESULTS: In COMET, 752/3029 patients (25%, 361 carvedilol and 391 metoprolol) had a non-fatal HF hospitalisation while on study treatment. Of these, 61 patients (8%) had beta-blocker treatment withdrawn, 162 (22%) had a dose reduction and 529 (70%) were maintained on the same dose. One-and two-year cumulative mortality rates were 28.7% and 44.6% for patients withdrawn from study medication, 37.4% and 51.4% for those with a reduced dosage (n.s.) and 19.1% and 32.5% for those maintained on the same dose (HR,1.59; 95%CI, 1.28-1.98; p<0.001, compared to the others). The result remained significant in a multivariable model: (HR, 1.30; 95%CI, 1.02-1.66; p=0.0318). No interaction with the beneficial effects of carvedilol, compared to metoprolol, on outcome was observed (p=0.8436).
CONCLUSIONS: HF hospitalisations are associated with a high subsequent mortality. The risk of death is higher in patients who discontinue beta-blocker therapy or have their dose reduced. The increase in mortality is only partially explained by the worse prognostic profile of these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17581778     DOI: 10.1016/j.ejheart.2007.05.011

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  20 in total

1.  Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation.

Authors:  Marco Metra; Luca Bettari; Franca Pagani; Valentina Lazzarini; Carlo Lombardi; Valentina Carubelli; Graziella Bonetti; Silvia Bugatti; Giovanni Parrinello; Luigi Caimi; G Michael Felker; Livio Dei Cas
Journal:  Clin Res Cardiol       Date:  2012-03-10       Impact factor: 5.460

2.  Incorporating Guideline Adherence and Practice Implementation Issues into the Design of Decision Support for Beta-Blocker Titration for Heart Failure.

Authors:  Michael W Smith; Charnetta Brown; Salim S Virani; Charlene R Weir; Laura A Petersen; Natalie Kelly; Julia Akeroyd; Jennifer H Garvin
Journal:  Appl Clin Inform       Date:  2018-06-27       Impact factor: 2.342

Review 3.  Evolving therapeutic strategies for patients hospitalized with new or worsening heart failure across the spectrum of left ventricular ejection fraction.

Authors:  John W Ostrominski; Muthiah Vaduganathan
Journal:  Clin Cardiol       Date:  2022-06       Impact factor: 3.287

Review 4.  Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis.

Authors:  Kurt W Prins; John M Neill; John O Tyler; Peter M Eckman; Sue Duval
Journal:  JACC Heart Fail       Date:  2015-08       Impact factor: 12.035

Review 5.  The influence of heart failure self-care on health outcomes: hypothetical cardioprotective mechanisms.

Authors:  Christopher S Lee; Nancy C Tkacs; Barbara Riegel
Journal:  J Cardiovasc Nurs       Date:  2009 May-Jun       Impact factor: 2.083

Review 6.  Causes and treatment of oedema in patients with heart failure.

Authors:  Andrew L Clark; John G F Cleland
Journal:  Nat Rev Cardiol       Date:  2013-01-15       Impact factor: 32.419

Review 7.  Determinants of survival following hospitalization for acute heart failure.

Authors:  Marwan F Jumean; Michael S Kiernan
Journal:  Curr Heart Fail Rep       Date:  2014-06

Review 8.  2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.

Authors:  Paul A Heidenreich; Gregg C Fonarow; Khadijah Breathett; Corrine Y Jurgens; Barbara A Pisani; Bunny J Pozehl; John A Spertus; Kenneth G Taylor; Jennifer T Thibodeau; Clyde W Yancy; Boback Ziaeian
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-11-02

9.  Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta-blockers in patients hospitalized for acute heart failure.

Authors:  Valentina Carubelli; Carlo Lombardi; Claudia Specchia; Giulia Peveri; Chiara Oriecuia; Daniela Tomasoni; Mattia Di Pasquale; Riccardo Inciardi; Emirena Garrafa; Marco Metra
Journal:  ESC Heart Fail       Date:  2021-03-04

10.  2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.

Authors:  Paul A Heidenreich; Gregg C Fonarow; Khadijah Breathett; Corrine Y Jurgens; Barbara A Pisani; Bunny J Pozehl; John A Spertus; Kenneth G Taylor; Jennifer T Thibodeau; Clyde W Yancy; Boback Ziaeian
Journal:  J Am Coll Cardiol       Date:  2020-11-02       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.